Topics

Glioblastoma | Treatment | Clinical trials

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials

□ OVERVIEW

CHEMOTHERAPY

□ CARBOPLATIN

□ LOMUSTINE

□ METHOXYAMINE

□ NEOADJUVANT CHEMOTHERAPY

□ R-(-)-GOSSYPOL

□ TAXANES

□ TEMOZOLOMIDE

ELECTRIC AND MAGNETIC FIELDS

□ TUMOR TREATING FIELDS

GENE THERAPY

□ AGLATIMAGENE BESADENOVEC

IMMUNOTHERAPY

□ BISPECIFIC ANTIBODY ARMED T CELLS

□ CAR-T-CELLS

□ CELL THERAPY

□ DENDRITIC CELLS

□ GM-CSF

□ IMMUNE CHECKPOINT INHIBITORS

□ VACCINES

□ VIRUSES

INTEGRATIVE MEDICINE

□ CIRCADIAN CLOCK

NUCLEAR MEDICINE

□ THERANOSTICS

PHARMACOTHERAPY

□ ARSENICALS

□ ANTIEPILEPTIC DRUGS

□ ANTISECRETORY FACTOR

□ DISULFIRAM

□ IMMUNOSUPPRESSIVE DRUGS

RADIOTHERAPY

□ MARGINS

□ PHOTODYNAMIC THERAPY

□ PROTON BEAM

□ RADIOPHARMACEUTICALS

□ RADIOSENSITIZERS

□ RE-IRRADIATION

□ RESPONSE-ADAPTIVE

SURGERY

□ 5-AMINOLEVULINICACID

□ BIOPSY

□ FLAIRECTOMY

□ RESECTION CAVITY

□ RESECTION EXTENT

TARGETED THERAPY

□ ADAVOSERTIB

□ AFATINIB

□ ANGIOGENES ISINHIBITORS

□ APTAMERS

□ GLUTAMATE SIGNALING INHIBITORS

□ IPILIMUMAB

□ KINASE INHIBITORS

□ LISAVANBULIN

□ MICROENVIRONMENT MODULATORS

□ NAVTEMADLIN

□ NIVOLUMAB

□ OLAPARIB

□ PEMBROLIZUMAB

□ PEXIDARTINIB

□ SACITUZUMAB GOVITECAN

□ SUNITINIB

□ TISLELIZUMAB

□ VELIPARIB